BEGIN:VCALENDAR
VERSION:2.0
PRODID:talks.ox.ac.uk
BEGIN:VEVENT
SUMMARY:Inhibition of the AAA-ATPase p97 with the first in class inhibitor
  CB-5083 as a novel approach to treat cancer - Dr Daniel Anderson (Cleave 
 Biosciences)
DTSTART;VALUE=DATE-TIME:20160907T110000
DTEND;VALUE=DATE-TIME:20160907T120000
UID:https://new.talks.ox.ac.uk/talks/id/69ed0ff5-36d3-4970-983a-7170248c19
 b9/
DESCRIPTION:Dr. Anderson has over 7 years of experience in cancer drug dis
 covery and early-stage research. Prior to joining Cleave in early 2012\, D
 r. Anderson contributed to a number of oncology-focused small molecule dru
 g discovery programs at Genentech. During this period he led a group respo
 nsible for developing novel cellular assays to report on drug activity and
  mechanism of action. His group contributed key mechanistic insights into 
 the function of clinically approved drugs targeting the MAPK pathway and a
 poptosis. Dr. Anderson received a PhD in cell biology and biochemistry fro
 m the University of California\, San Diego in conjunction with the Salk In
 stitute where he was awarded the Martin D. Kamen Cell Biology Thesis Prize
 . He earned his BS degree in Biology from the University of Pittsburgh. Dr
 . Anderson has authored over 20 scientific publications including several 
 in top-tier journals.\nSpeakers:\nDr Daniel Anderson (Cleave Biosciences)
LOCATION:NDM Building (Seminar Room)\, Headington OX3 7FZ
TZID:Europe/London
URL:https://new.talks.ox.ac.uk/talks/id/69ed0ff5-36d3-4970-983a-7170248c19
 b9/
BEGIN:VALARM
ACTION:display
DESCRIPTION:Talk:Inhibition of the AAA-ATPase p97 with the first in class 
 inhibitor CB-5083 as a novel approach to treat cancer - Dr Daniel Anderson
  (Cleave Biosciences)
TRIGGER:-PT1H
END:VALARM
END:VEVENT
END:VCALENDAR